Covestor’s Axsome Therapeutics AXSM Stock Holding History

Covestor’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64K	Buy	262 +70	+36%	+$15.2K	0.04%	642
2026 Q1	$32K	Sell	192 -407	-68%	-$70.3K	0.02%	929
2025 Q4	$110K	Buy	599 +98	+20%	+$13.7K	0.06%	524
2025 Q3	$61K	Buy	501 +374	+294%	+$42.1K	0.03%	819
2025 Q2	$13K	Sell	127 -1	-0.8%	-$106	0.01%	1397
2025 Q1	$15K	Buy	128 +1	+0.8%	+$114	0.01%	1279
2024 Q4	$11K	Hold	127	–	–	0.01%	1461
2024 Q3	$11K	Sell	127 -880	-87%	-$76.8K	0.01%	1474
2024 Q2	$81K	Sell	1,007 -90	-8%	-$6.66K	0.05%	616
2024 Q1	$88K	Buy	1,097 +1,095	+54,750%	+$91.9K	0.06%	619
2023 Q4	$0	Hold	2	–	–	﹤0.01%	2136
2023 Q3	$0	Hold	2	–	–	﹤0.01%	2108
2023 Q2	$0	Sell	2 -2	-50%	-$148	﹤0.01%	2125
2023 Q1	$0	Hold	4	–	–	﹤0.01%	2011
2022 Q4	$0	Hold	4	–	–	﹤0.01%	2058
2022 Q3	$0	Sell	4 -3	-43%	-$150	﹤0.01%	1976
2022 Q2	$0	Sell	7 -2	-22%	-$63	﹤0.01%	1899
2022 Q1	$0	Sell	9 -2	-18%	-$62	﹤0.01%	2097
2021 Q4	$0	Buy	+11	New	+$405	﹤0.01%	2107

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Covestor's AXSM Position: Q2 2026 in Review

Covestor increased its Axsome Therapeutics (AXSM) stake by 36% in Q2 2026, buying an estimated $15.2K and bringing the position to 262 shares worth $64K. The position accounts for 0.04% of the portfolio, ranked #642.

Covestor first reported a position in AXSM in Q4 2021 and has held it in 19 quarters since. The position peaked at $110K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Covestor held 262 shares of Axsome Therapeutics worth $64K as of Q2 2026.
Covestor bought 70 Axsome Therapeutics shares in Q2 2026, an estimated $15.2K.
Axsome Therapeutics made up 0.04% of Covestor's portfolio in Q2 2026, its #642 holding.
Covestor first reported a position in Axsome Therapeutics in Q4 2021 and has held it in 19 quarters since.
Covestor's Axsome Therapeutics position peaked at $110K in Q4 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.